SMO (SMOOTHENED TRANSMEMBRANE PROTEIN) INHIBITORS (VISMODEGIB) IN TREATMENT OF BASAL CELL CARCINOMA (BCC) OF OCULAR ADNEXA

• Egile Nagusiak: Georgi Balchev (Egilea), Chavdar Balabanov (Egilea), Snezhana Murgova (Egilea)
• Formatua: Liburua
• Argitaratua: Peytchinski Publishing, 2020-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Basal Cell Carcinoma (BCC) is one of the well spread malignant skin cancers. Eighty percent of it occurs in the head-neck area of which 20% in the eyelids. The major genes for BCC are: PTCH1 and PTCH2. PTCH1 supresses transmembrane Smoothened (SMO) protein, while PTCH2 have his role uncleared, but t...